Navigation Links
Sugammadex Trials Demonstrate Rapid Recovery from Profound Neuromuscular Blockade During General Anesthesia
Date:10/16/2007

SAN FRANCISCO, Oct. 16 /PRNewswire/ -- Sugammadex -- the novel selective relaxant binding agent (SRBA) being developed by Organon -- demonstrated a faster recovery from profound neuromuscular blockade as compared to neostigmine in the Phase III pivotal Signal trial.(1) In a second trial, named Spectrum, faster recovery from profound neuromuscular blockade compared to spontaneous recovery was demonstrated.(2) The pivotal Signal trial results were presented today at the 2007 annual meeting of the American Society of Anesthesiologists (ASA) taking place in San Francisco from October 13-17. The Spectrum trial results were presented on October 14.

The Signal trial compared the efficacy and safety of sugammadex and neostigmine/glycopyrrolate for the reversal of profound rocuronium (Zemuron(R)/ Esmeron(R)/Eslax(R)) induced neuromuscular blockade. The Spectrum trial compared the efficacy and safety of sugammadex for reversal of profound rocuronium-induced neuromuscular blockade with that of spontaneous recovery from succinylcholine-induced blockade.

"The Signal trial results are clinically significant for anesthesiologists during neuromuscular blockade management, as with sugammadex they will be able to have control when using any depth of rocuronium-induced neuromuscular, and be able to reverse the blockade rapidly at any moment they want, which is not possible with current treatments," said Professor James E. Caldwell, University of California, San Francisco and one of the lead Signal trial investigators.

Reversal agents are used during general anesthesia to reverse the effects of muscle relaxants, also called neuromuscular blocking agents (NMBAs). Reversal of neuromuscular blockade enables spontaneous breathing to recommence earlier which helps to get patients out of the operating room quicker, freeing up capacity and personnel to help additional patients. Adequate reversal reduces the risk of residual paralysis, which may cause a number of serio
'/>"/>

SOURCE Organon
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Organons Sugammadex Demonstrated a 9-12 Times Faster Recovery in Phase III Pivotal Trial as Compared to Neostigmine
2. Organons Sugammadex Demonstrated a 9-12 Times Faster Recovery in Phase III Pivotal Trial Compared to Neostigmine
3. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
4. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
5. TMC125 Showed Significant Virologic Response at Week 24 in Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3 Trials
6. From Clinical Cancer Research: Rethinking Therapeutic Cancer Vaccine Trials
7. Advanced Life Sciences to Host Conference Call to Discuss Data From Cethromycins First of Two Phase 3 Pneumonia Trials
8. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
9. Two Phase III clinical trials on corifollitropin alfa (Org 36286) reach randomization target
10. Pharmacyclics Announces Interim Results From Two Ongoing Phase 2 Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat Recurrent Non-Small Cell Lung Cancer
11. Neurogen Announces Positive Results for Proprietary Insomnia Drug in Two Chronic Insomnia Clinical Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... , Jan. 23, 2015  Mallinckrodt plc (NYSE: ... has approved a share repurchase program. The open-ended authorization ... of Mallinckrodt plc ordinary shares. "Funding ... top priorities as we continue to pursue a range ...
(Date:1/22/2015)... , Jan. 22, 2015  ViewRay™, a privately held ... into an exclusive distributor agreement with ITOCHU Corporation (Tokyo ... therapy system for the treatment of cancer in ... system, is the world,s first and only MRI-guided radiation ...
(Date:1/22/2015)... 22, 2015 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ("Pivotal" or ... Omega-3 therapies for cardiovascular disease and overall health is pleased ... in 2014 and its outlook for 2015 from the CEO, ... We would like to take this opportunity to ...
Breaking Medicine Technology:Mallinckrodt plc Announces Share Repurchase Program 2Mallinckrodt plc Announces Share Repurchase Program 3Mallinckrodt plc Announces Share Repurchase Program 4ITOCHU Named the Exclusive Distributor for ViewRay's MRI-Guided Radiation Therapy System in Japan 2Pivotal Therapeutics: Year in Review and CEO Update 2Pivotal Therapeutics: Year in Review and CEO Update 3Pivotal Therapeutics: Year in Review and CEO Update 4Pivotal Therapeutics: Year in Review and CEO Update 5Pivotal Therapeutics: Year in Review and CEO Update 6Pivotal Therapeutics: Year in Review and CEO Update 7
... Advocate Christ,Medical Center in Oak Lawn, Ill. has ... area, the only one in the Advocate Health Care ... a glue-like liquid for,the successful treatment of brain aneurysms ... J. Grobelny MD, of,the medical center,s Neurosciences Institute, led ...
... 19 Trubion Pharmaceuticals Inc.,(Nasdaq: TRBN ) ... (NYSE: WYE ), has exercised its option ... to extend the research period for an,additional one-year ... of the,research period extension, Wyeth,s obligations to Trubion ...
Cached Medicine Technology:Advocate Christ Medical Center Using Glue-Like Liquid to Seal Off Brain Aneurysms 2Trubion Pharmaceuticals Announces Extension of Research Period Under Its Wyeth Collaboration 2Trubion Pharmaceuticals Announces Extension of Research Period Under Its Wyeth Collaboration 3
(Date:1/22/2015)... (PRWEB) January 23, 2015 LunaDress, with its ... the fashion industry. Now, the business is showing its latest ... women’s dresses. , According to the company’s CEO, all the ... now offered with big discounts, up to 80% off. All ...
(Date:1/22/2015)... 22, 2015 Gabe’s Chemo Duck Program is pleased ... first app ever created for kids with cancer. The Chemo Duck ... devices, is filled with enjoyable games to help children of all ... free app helps to keep kids entertained, educated and at ease ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 The Incredible Bulk ... Ben Pakulski to increase lean muscle by up to 30lbs ... caught the attention of HealthyandFitZone.com’s Stan Stevenson, prompting an investigative ... it is a step-by-step, scientific diet formula that allows the ...
(Date:1/22/2015)... AngelWeddingDress, the premier women’s dress supplier, ... dresses. View website of AngelWeddingDress.com to find ... wedding dresses online for a bridal party. AngelWeddingDress offers ... for them. Its maternity wedding dresses are specially designed ...
(Date:1/22/2015)... 22, 2015 A new white paper ... and person-centeredness in the long-term care environment as well ... the continuum. The paper, “The Power of Person-Centeredness in ... and practices of the patient, resident and family experience ...
Breaking Medicine News(10 mins):Health News:LunaDress Shows The Latest Styles Of Wedding Dresses In 2015 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 3Health News:The Incredible Bulk: Review Examining Ben Pakulski’s Brand New Bulking Muscle Building Diet Program Released 2Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3
... WASHINGTON, Feb. 2 Danaher Corporation (NYSE: ... Financial Officer, Daniel L. Comas will be presenting at ... on Monday, February 9, 2009 at 1:35 p.m. EST. ... . A replay of the webcast will be available ...
... (Nasdaq: DRAD ), a leading provider of ... that improve patient care while driving positive healthcare economics, ... to three northern California service hub locations. The ... Office Solutions calls for the sale of portable nuclear ...
... be considered, AHA panel says , , MONDAY, Feb. 2 ... should be used cautiously to minimize patient exposure to ... That,s the conclusion of a new American Heart Association ... Circulation . , Sources of ionizing radiation include ...
... contradicting previous research , , MONDAY, Feb. 2 (HealthDay News) ... decline among the elderly, new research shows. , The ... lowered the risk for Alzheimer,s disease and dementia. , ... the number of years of schooling you,ve had," said ...
... Ohio, Feb. 2 The National Committee for Quality,Assurance ... as a New,Health Plan for its Medicaid program through ... , NCQA Accreditation is based ... get high-quality care. Accreditation evaluates not only the health,plan,s ...
... overestimate their actual risk of medical malpractice lawsuits, according to ... Public Health and Community Medicine in Seattle, WA. , ... one in 2006 that asked radiologists in diverse regions of ... malpractice claim related to mammography? And what do you think ...
Cached Medicine News:Health News:Digirad Corporation Sells Northern California Service Hubs 2Health News:Experts Urge Limits on Use of Cardiac CT Scans 2Health News:Education Doesn't Slow Alzheimer's Decline 2Health News:Unison Health Plan of Ohio Accredited by NCQA 2
... cutting speeds (guillotine movements) are possible. Cutting ... off, thus minimizing tissue trauma. One can ... both can be combined together. There are ... bi-manual techniques. Lightweight autoclavable hand-pieces with single ...
A wide selection of bipolar forceps and hemostatic erasers to facilitate most ophthalmic surgical procedures....
Enables Delicate Lifting Of The Flap Without Causing Trauma - Also available in Titanium...
The CGIL iridectomy contact glass was designed by Riquin, Fankhauser et al. to perform full thickness peripheral laser iridectomies....
Medicine Products: